HRP20050535A2 - C-6 modified indazolylpyrrolotriazines - Google Patents

C-6 modified indazolylpyrrolotriazines Download PDF

Info

Publication number: HRP20050535A2
Authority: HR; Croatia
Prior art keywords: indazol; pyrrolo; ethyl; amino; methyl
Prior art date: 2002-12-13

Application number

HR20050535A

Other languages

English (en)

Croatian (hr)

Inventor

D. Vite Gregory

E. Fink Brian

F. Kadow John

V. Gavai Ashvinikumar

Mastalerz Harold

Original Assignee

Bristol-Myers Squibb Company A Delaware (Usa) Corp

Oration

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2002-12-13

Filing date

2003-12-12

Publication date

2005-12-31

2003-12-12 Application filed by Bristol-Myers Squibb Company A Delaware (Usa) Corp, Oration filed Critical Bristol-Myers Squibb Company A Delaware (Usa) Corp

2005-12-31 Publication of HRP20050535A2 publication Critical patent/HRP20050535A2/hr

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Animal Behavior & Ethology (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Physical Education & Sports Medicine (AREA)
Immunology (AREA)
Rheumatology (AREA)
Urology & Nephrology (AREA)
Orthopedic Medicine & Surgery (AREA)
Dermatology (AREA)
Pain & Pain Management (AREA)
Biomedical Technology (AREA)
Epidemiology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Nitrogen Condensed Heterocyclic Rings (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Inks, Pencil-Leads, Or Crayons (AREA)
Agricultural Chemicals And Associated Chemicals (AREA)

HR20050535A 2002-12-13 2003-12-12 C-6 modified indazolylpyrrolotriazines HRP20050535A2 (en)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US43319002P	2002-12-13	2002-12-13
PCT/US2003/039542 WO2004054514A2 (en)	2002-12-13	2003-12-12	C-6 modified indazolylpyrrolotriazines

Publications (1)

Publication Number	Publication Date
HRP20050535A2 true HRP20050535A2 (en)	2005-12-31

Family

ID=32595133

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
HR20050535A HRP20050535A2 (en)	2002-12-13	2003-12-12	C-6 modified indazolylpyrrolotriazines

Country Status (27)

Country	Link
US (2)	US6916815B2 (es)
EP (1)	EP1569937B1 (es)
JP (1)	JP4511367B2 (es)
KR (1)	KR101073801B1 (es)
CN (2)	CN1726216A (es)
AR (1)	AR042450A1 (es)
AT (1)	ATE534648T1 (es)
AU (1)	AU2003300877B2 (es)
BR (1)	BR0316755A (es)
CA (1)	CA2509650C (es)
CO (1)	CO5570660A2 (es)
DK (1)	DK1569937T3 (es)
ES (1)	ES2374393T3 (es)
HR (1)	HRP20050535A2 (es)
IS (1)	IS7890A (es)
MX (1)	MXPA05006164A (es)
NO (1)	NO20052733L (es)
NZ (1)	NZ540338A (es)
PE (1)	PE20040805A1 (es)
PL (1)	PL377517A1 (es)
PT (1)	PT1569937E (es)
RS (1)	RS20050441A (es)
RU (1)	RU2356903C2 (es)
TW (1)	TW200420565A (es)
UA (1)	UA80591C2 (es)
WO (1)	WO2004054514A2 (es)
ZA (1)	ZA200504507B (es)

Families Citing this family (62)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JP4579351B2 (ja)	1996-12-03	2010-11-10	スローン−ケッタリングインスティトュートフォアキャンサーリサーチ	エポチロンの合成とその中間体及びその類似物並びにその使用
US7625859B1 (en) *	2000-02-16	2009-12-01	Oregon Health & Science University	HER-2 binding antagonists
US7393823B1 (en)	1999-01-20	2008-07-01	Oregon Health And Science University	HER-2 binding antagonists
US6867300B2 (en)	2000-11-17	2005-03-15	Bristol-Myers Squibb Company	Methods for the preparation of pyrrolotriazine compounds useful as kinase inhibitors
US20090197852A9 (en) *	2001-08-06	2009-08-06	Johnson Robert G Jr	Method of treating breast cancer using 17-AAG or 17-AG or a prodrug of either in combination with a HER2 inhibitor
ATE418546T1 (de)	2002-04-23	2009-01-15	Bristol Myers Squibb Co	Als kinase inhibitoren geeignete arylketonpyrrolotriazin-verbindungen
WO2003090912A1 (en)	2002-04-23	2003-11-06	Bristol-Myers Squibb Company	Pyrrolo-triazine aniline compounds useful as kinase inhibitors
TWI329112B (en) *	2002-07-19	2010-08-21	Bristol Myers Squibb Co	Novel inhibitors of kinases
US6921769B2 (en)	2002-08-23	2005-07-26	Sloan-Kettering Institute For Cancer Research	Synthesis of epothilones, intermediates thereto and analogues thereof
US7649006B2 (en)	2002-08-23	2010-01-19	Sloan-Kettering Institute For Cancer Research	Synthesis of epothilones, intermediates thereto and analogues thereof
NZ538522A (en)	2002-08-23	2008-03-28	Sloan Kettering Inst Cancer	Synthesis of epothilones, intermediates thereto, analogues and uses thereof
TW200420565A (en) *	2002-12-13	2004-10-16	Bristol Myers Squibb Co	C-6 modified indazolylpyrrolotriazines
PL378121A1 (pl)	2003-02-05	2006-03-06	Bristol-Myers Squibb Company	Sposób wytwarzania pirolotriazynowych inhibitorów kinazy
ES2428358T3 (es) *	2003-10-17	2013-11-07	Novo Nordisk A/S	Terapia de combinación
US20060014741A1 (en) *	2003-12-12	2006-01-19	Dimarco John D	Synthetic process, and crystalline forms of a pyrrolotriazine compound
US7102001B2 (en)	2003-12-12	2006-09-05	Bristol-Myers Squibb Company	Process for preparing pyrrolotriazine
MY145634A (en)	2003-12-29	2012-03-15	Bristol Myers Squibb Co	Pyrrolotriazine compounds as kinase inhibitors
US7064203B2 (en) *	2003-12-29	2006-06-20	Bristol Myers Squibb Company	Di-substituted pyrrolotriazine compounds
US7459562B2 (en)	2004-04-23	2008-12-02	Bristol-Myers Squibb Company	Monocyclic heterocycles as kinase inhibitors
TW200538453A (en)	2004-04-26	2005-12-01	Bristol Myers Squibb Co	Bicyclic heterocycles as kinase inhibitors
US7102002B2 (en) *	2004-06-16	2006-09-05	Bristol-Myers Squibb Company	Pyrrolotriazine kinase inhibitors
US20050288290A1 (en)	2004-06-28	2005-12-29	Borzilleri Robert M	Fused heterocyclic kinase inhibitors
US7432373B2 (en)	2004-06-28	2008-10-07	Bristol-Meyers Squibb Company	Processes and intermediates useful for preparing fused heterocyclic kinase inhibitors
US7439246B2 (en)	2004-06-28	2008-10-21	Bristol-Myers Squibb Company	Fused heterocyclic kinase inhibitors
TW200600513A (en) *	2004-06-30	2006-01-01	Bristol Myers Squibb Co	A method for preparing pyrrolotriazine compounds
US7253167B2 (en) *	2004-06-30	2007-08-07	Bristol-Myers Squibb Company	Tricyclic-heteroaryl compounds useful as kinase inhibitors
US7102003B2 (en) *	2004-07-01	2006-09-05	Bristol-Myers Squibb Company	Pyrrolotriazine compounds
US7504521B2 (en)	2004-08-05	2009-03-17	Bristol-Myers Squibb Co.	Methods for the preparation of pyrrolotriazine compounds
PE20060421A1 (es)	2004-08-12	2006-06-01	Bristol Myers Squibb Co	Procedimiento para preparar un compuesto de pirrolotriazina anilina como inhibidores de cinasa
EP1807106A2 (en) *	2004-10-05	2007-07-18	Oregon Health and Science University	Compositions and methods for treating disease
US7151176B2 (en) *	2004-10-21	2006-12-19	Bristol-Myers Squibb Company	Pyrrolotriazine compounds
RU2412199C2 (ru)	2005-04-18	2011-02-20	Ново Нордиск А/С	Варианты ил-21
US7402582B2 (en) *	2005-07-01	2008-07-22	Bristol-Myers Squibb Company	Pyrrolotriazine compounds useful as kinase inhibitors and methods of treating kinase-associated conditions therewith
US7405213B2 (en) *	2005-07-01	2008-07-29	Bristol-Myers Squibb Company	Pyrrolotriazine compounds useful as kinase inhibitors and methods of treating kinase-associated conditions therewith
US7880004B2 (en)	2005-09-15	2011-02-01	Bristol-Myers Squibb Company	Met kinase inhibitors
US7547782B2 (en)	2005-09-30	2009-06-16	Bristol-Myers Squibb Company	Met kinase inhibitors
US7514435B2 (en) *	2005-11-18	2009-04-07	Bristol-Myers Squibb Company	Pyrrolotriazine kinase inhibitors
US7348325B2 (en)	2005-11-30	2008-03-25	Bristol-Myers Squibb Company	Pyrrolotriazine kinase inhibitors
US8063208B2 (en)	2006-02-16	2011-11-22	Bristol-Myers Squibb Company	Crystalline forms of (3R,4R)-4-amino-1-[[4-[(3-methoxyphenyl)amino]pyrrolo[2,1-f][1,2,4]triazin-5-yl]methyl]piperidin-3-ol
JP2009535295A (ja)	2006-03-07	2009-10-01	ブリストル−マイヤーズスクイブカンパニー	キナーゼ阻害剤として有用なピロロトリアジンアニリンプロドラッグ化合物
CA2666426A1 (en)	2006-10-26	2008-05-02	Novo Nordisk A/S	Il-21 variants
EP2109620B1 (en) *	2006-12-21	2012-08-22	Novo Nordisk A/S	Interleukin-21 variants with altered binding to the il-21 receptor
US20090083483A1 (en) *	2007-09-24	2009-03-26	International Business Machines Corporation	Power Conservation In A RAID Array
US8166326B2 (en) *	2007-11-08	2012-04-24	International Business Machines Corporation	Managing power consumption in a computer
US20090132842A1 (en) *	2007-11-15	2009-05-21	International Business Machines Corporation	Managing Computer Power Consumption In A Computer Equipment Rack
US8041521B2 (en) *	2007-11-28	2011-10-18	International Business Machines Corporation	Estimating power consumption of computing components configured in a computing system
EP2268637A1 (en)	2008-04-04	2011-01-05	Gilead Sciences, Inc.	Triazolopyridinone derivatives for use as stearoyl coa desaturase inhibitors
CA2719362A1 (en) *	2008-04-04	2009-10-08	Gilead Sciences, Inc.	Pyrrolotriazinone derivatives for use as stearoyl coa desaturase inhibitors
US20110086850A1 (en) *	2008-04-11	2011-04-14	Board Of Regents, The University Of Texas System	Radiosensitization of tumors with indazolpyrrolotriazines for radiotherapy
US8103884B2 (en)	2008-06-25	2012-01-24	International Business Machines Corporation	Managing power consumption of a computer
US8041976B2 (en) *	2008-10-01	2011-10-18	International Business Machines Corporation	Power management for clusters of computers
US8514215B2 (en) *	2008-11-12	2013-08-20	International Business Machines Corporation	Dynamically managing power consumption of a computer with graphics adapter configurations
WO2010071885A1 (en)	2008-12-19	2010-06-24	Cephalon, Inc.	Pyrrolotriazines as alk and jak2 inhibitors
CA2754909A1 (en) *	2009-03-11	2010-09-16	Ambit Biosciences Corp.	Combination of an indazolylaminopyrrolotriazine and taxane for cancer treatment
WO2011112689A2 (en)	2010-03-11	2011-09-15	Ambit Biosciences Corp.	Saltz of an indazolylpyrrolotriazine
US9724352B2 (en)	2012-05-31	2017-08-08	Shanghai Institute Of Materia Medica, Chinese Academy Of Sciences	Pyrrolo[2,1-F[1,2,4]triazine compounds, preparation methods and applications thereof
CN103450204B (zh)	2012-05-31	2016-08-17	中国科学院上海药物研究所	吡咯[2，1-f][1，2，4]并三嗪类化合物，其制备方法及用途
WO2014143607A1 (en) *	2013-03-11	2014-09-18	Bristol-Myers Squibb Company	Pyrrolopyridazines as potassium ion channel inhibitors
WO2014143606A1 (en) *	2013-03-11	2014-09-18	Bristol-Myers Squibb Company	Pyrrolotriazines as potassium ion channel inhibitors
US9050345B2 (en) *	2013-03-11	2015-06-09	Bristol-Myers Squibb Company	Pyrrolotriazines as potassium ion channel inhibitors
WO2015081783A1 (zh) *	2013-12-06	2015-06-11	江苏奥赛康药业股份有限公司	吡咯并[2,1-f][1,2,4]三嗪类衍生物及其制备方法和用途
CN111533708B (zh) *	2020-06-12	2021-03-16	上海馨远医药科技有限公司	一种手性n-叔丁氧羰基吗啉-3-羧酸的制备方法

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4908056A (en) *	1986-04-25	1990-03-13	E. I. Du Pont De Nemours And Company	Heterocyclic acyl sulfonamides
ES2200039T3 (es)	1995-12-08	2004-03-01	Pfizer Inc.	Derivados heterociclicos sustituidos como antagonistas de crf.
TR199900389T2 (xx)	1996-08-28	2000-06-21	Pfizer Inc.	�kame edilmi� 6,5-hetero-bisiklik t�revleri.
EP1183033B1 (en) *	1999-05-21	2006-03-01	Bristol-Myers Squibb Company	Pyrrolotriazine inhibitors of kinases
JP4623483B2 (ja)	1999-08-23	2011-02-02	塩野義製薬株式会社	ｓＰＬＡ２阻害作用を有するピロロトリアジン誘導体
GEP20063915B (en) *	2000-11-17	2006-09-11	Bristol Myers Squibb Co	PYRROLOTRIAZINE COMPOUNDS USEFUL AS KINASE INHIBITORS AND USE THEREOF FOR TREATING p38 KINASE-ASSOCIATED CONDITIONS
US6867300B2 (en)	2000-11-17	2005-03-15	Bristol-Myers Squibb Company	Methods for the preparation of pyrrolotriazine compounds useful as kinase inhibitors
TW200300350A (en)	2001-11-14	2003-06-01	Bristol Myers Squibb Co	C-5 modified indazolylpyrrolotriazines
WO2003090912A1 (en) *	2002-04-23	2003-11-06	Bristol-Myers Squibb Company	Pyrrolo-triazine aniline compounds useful as kinase inhibitors
ATE418546T1 (de) *	2002-04-23	2009-01-15	Bristol Myers Squibb Co	Als kinase inhibitoren geeignete arylketonpyrrolotriazin-verbindungen
TW200400034A (en) *	2002-05-20	2004-01-01	Bristol Myers Squibb Co	Pyrazolo-pyrimidine aniline compounds useful as kinase inhibitors
TWI329112B (en)	2002-07-19	2010-08-21	Bristol Myers Squibb Co	Novel inhibitors of kinases
TW200420565A (en) *	2002-12-13	2004-10-16	Bristol Myers Squibb Co	C-6 modified indazolylpyrrolotriazines
US7102001B2 (en) *	2003-12-12	2006-09-05	Bristol-Myers Squibb Company	Process for preparing pyrrolotriazine

2003
- 2003-12-08 TW TW092134601A patent/TW200420565A/zh unknown
- 2003-12-12 RU RU2005120650/04A patent/RU2356903C2/ru not_active IP Right Cessation
- 2003-12-12 AU AU2003300877A patent/AU2003300877B2/en not_active Ceased
- 2003-12-12 RS YUP-2005/0441A patent/RS20050441A/sr unknown
- 2003-12-12 AT AT03813396T patent/ATE534648T1/de active
- 2003-12-12 PT PT03813396T patent/PT1569937E/pt unknown
- 2003-12-12 ES ES03813396T patent/ES2374393T3/es not_active Expired - Lifetime
- 2003-12-12 CA CA002509650A patent/CA2509650C/en not_active Expired - Fee Related
- 2003-12-12 UA UAA200506891A patent/UA80591C2/uk unknown
- 2003-12-12 KR KR1020057010549A patent/KR101073801B1/ko not_active Expired - Fee Related
- 2003-12-12 DK DK03813396.3T patent/DK1569937T3/da active
- 2003-12-12 PL PL377517A patent/PL377517A1/pl not_active Application Discontinuation
- 2003-12-12 HR HR20050535A patent/HRP20050535A2/hr not_active Application Discontinuation
- 2003-12-12 CN CNA200380105906XA patent/CN1726216A/zh active Pending
- 2003-12-12 EP EP03813396A patent/EP1569937B1/en not_active Expired - Lifetime
- 2003-12-12 NZ NZ540338A patent/NZ540338A/en not_active IP Right Cessation
- 2003-12-12 JP JP2004560804A patent/JP4511367B2/ja not_active Expired - Fee Related
- 2003-12-12 WO PCT/US2003/039542 patent/WO2004054514A2/en not_active Ceased
- 2003-12-12 PE PE2003001275A patent/PE20040805A1/es not_active Application Discontinuation
- 2003-12-12 BR BR0316755-0A patent/BR0316755A/pt not_active IP Right Cessation
- 2003-12-12 MX MXPA05006164A patent/MXPA05006164A/es active IP Right Grant
- 2003-12-12 AR ARP030104592A patent/AR042450A1/es unknown
- 2003-12-12 CN CN200910246410A patent/CN101723948A/zh active Pending
- 2003-12-15 US US10/736,476 patent/US6916815B2/en not_active Expired - Fee Related
2005
- 2005-06-01 ZA ZA200504507A patent/ZA200504507B/en unknown
- 2005-06-02 US US11/143,279 patent/US7148220B2/en not_active Expired - Fee Related
- 2005-06-07 NO NO20052733A patent/NO20052733L/no not_active Application Discontinuation
- 2005-06-10 IS IS7890A patent/IS7890A/is unknown
- 2005-06-13 CO CO05057043A patent/CO5570660A2/es not_active Application Discontinuation

Also Published As

Publication number	Publication date
CO5570660A2 (es)	2005-10-31
JP2006509826A (ja)	2006-03-23
ATE534648T1 (de)	2011-12-15
NO20052733D0 (no)	2005-06-07
WO2004054514A3 (en)	2004-10-07
PT1569937E (pt)	2012-01-04
TW200420565A (en)	2004-10-16
US6916815B2 (en)	2005-07-12
KR101073801B1 (ko)	2011-10-13
UA80591C2 (en)	2007-10-10
EP1569937B1 (en)	2011-11-23
RU2356903C2 (ru)	2009-05-27
EP1569937A2 (en)	2005-09-07
US20040142931A1 (en)	2004-07-22
CN101723948A (zh)	2010-06-09
AR042450A1 (es)	2005-06-22
BR0316755A (pt)	2005-10-25
US20050222153A1 (en)	2005-10-06
WO2004054514A2 (en)	2004-07-01
CA2509650A1 (en)	2004-07-01
IS7890A (is)	2005-06-10
NO20052733L (no)	2005-07-07
JP4511367B2 (ja)	2010-07-28
AU2003300877B2 (en)	2010-02-18
KR20050084242A (ko)	2005-08-26
DK1569937T3 (da)	2012-01-02
NZ540338A (en)	2008-05-30
EP1569937A4 (en)	2007-08-08
PL377517A1 (pl)	2006-02-06
AU2003300877A1 (en)	2004-07-09
ES2374393T3 (es)	2012-02-16
RS20050441A (sr)	2007-04-10
RU2005120650A (ru)	2006-01-20
PE20040805A1 (es)	2004-11-20
CA2509650C (en)	2007-10-30
US7148220B2 (en)	2006-12-12
MXPA05006164A (es)	2005-08-26
ZA200504507B (en)	2006-08-30
CN1726216A (zh)	2006-01-25

Publication	Publication Date	Title
HRP20050535A2 (en)	2005-12-31	C-6 modified indazolylpyrrolotriazines
US6951859B2 (en)	2005-10-04	Pyrrolotriazine kinase inhibitors
DE60026297T2 (de)	2006-11-02	Pyrrolotriazin kinasehemmer
ES2370709T3 (es)	2011-12-22	Indazolilpirrolotrizinas con c5 modificadas.
US7112675B2 (en)	2006-09-26	Pyrrolotriazine inhibitors of kinases
US20070149534A1 (en)	2007-06-28	Pyrrolotriazine kinase inhibitors
HRP20050058A2 (en)	2005-08-31	Azaindole kinase inhibitors
US7151176B2 (en)	2006-12-19	Pyrrolotriazine compounds
US7102003B2 (en)	2006-09-05	Pyrrolotriazine compounds
US7087621B2 (en)	2006-08-08	Benzo- and azabenzodithiazole compounds

Legal Events

Date	Code	Title	Description
2005-12-31	A1OB	Publication of a patent application
2006-02-10	ARAI	Request for the grant of a patent on the basis of the submitted results of a substantive examination of a patent application
2007-12-11	ODRP	Renewal fee for the maintenance of a patent	Payment date: 20071211 Year of fee payment: 5
2009-06-17	OBST	Application withdrawn